Literature DB >> 33152576

Decreased overall survival in black patients with HPV-associated oropharyngeal cancer.

Siddharth Sheth1, Douglas R Farquhar2, Nicholas R Lenze2, Angela Mazul3, Paul Brennan4, Devasena Anantharaman4, Behnoush Abedi-Ardekani4, Jose P Zevallos3, D Neil Hayes5, F Olshan6.   

Abstract

PURPOSE: Racial disparities for overall survival (OS) in head and neck cancer have been well described. However, the extent to which these disparities exist for HPV-associated oropharyngeal squamous cell carcinoma (OPSCC), and the contribution of demographic, clinical, and socioeconomic status (SES) variables, is unknown.
MATERIALS AND METHODS: Patients were identified from the Carolina Head and Neck Cancer Epidemiology Study (CHANCE), a population-based study in North Carolina. Cox proportional hazards regression models were used to estimate hazard ratios (HR) and 95% confidence intervals (CI) for OS in black versus white patients with sequential adjustment sets.
RESULTS: A total of 157 HPV-associated OPSCC patients were identified. Of these, 93% were white and 7% were black. Black patients with HPV-associated OPSCC were more likely to be younger, have an income <$20,000, live farther away from clinic where biopsy was performed, and have advanced T stage at diagnosis. Black patients had worse OS in the unadjusted analysis (HR 4.9, 95% CI 2.2-11.1, p < 0.0001). The racial disparity in OS slightly decreased when sequentially adjusting for demographic, clinical, and SES variables. However, HR for black race remained statistically elevated in the final adjustment set which controlled for age, sex, stage, smoking, alcohol use, and individual-level household income, insurance, and education level (HR 3.4, 95% CI 1.1-10.1, p = 0.028).
CONCLUSION: This is the first population-based study that confirms persistence of racial disparities in HPV-associated OPSCC after controlling for demographic, clinical, and individual-level socioeconomic factors.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Disparities; Head and neck neoplasms; Human papillomavirus; Race; Survival

Mesh:

Year:  2020        PMID: 33152576      PMCID: PMC7988501          DOI: 10.1016/j.amjoto.2020.102780

Source DB:  PubMed          Journal:  Am J Otolaryngol        ISSN: 0196-0709            Impact factor:   1.808


  32 in total

Review 1.  HPV-associated head and neck cancer: a virus-related cancer epidemic.

Authors:  Shanthi Marur; Gypsyamber D'Souza; William H Westra; Arlene A Forastiere
Journal:  Lancet Oncol       Date:  2010-05-05       Impact factor: 41.316

2.  Impact of African-American race on presentation, treatment, and survival of head and neck cancer.

Authors:  Brandon A Mahal; Gino Inverso; Ayal A Aizer; R Bruce Donoff; Sung-Kiang Chuang
Journal:  Oral Oncol       Date:  2014-09-26       Impact factor: 5.337

3.  Neighborhood deprivation and clinical outcomes among head and neck cancer patients.

Authors:  Lorraine R Reitzel; Nga Nguyen; Mark E Zafereo; Guojun Li; Qingyi Wei; Erich M Sturgis
Journal:  Health Place       Date:  2012-03-14       Impact factor: 4.078

Review 4.  Evidence of past dental visits and incidence of head and neck cancers: a systematic review and meta-analysis.

Authors:  Bhawna Gupta; Narinder Kumar; Newell W Johnson
Journal:  Syst Rev       Date:  2019-02-04

5.  Case-matching analysis of head and neck squamous cell carcinoma in racial and ethnic minorities in the United States--possible role for human papillomavirus in survival disparities.

Authors:  Travis P Schrank; Yimei Han; Heidi Weiss; Vicente A Resto
Journal:  Head Neck       Date:  2011-01       Impact factor: 3.147

6.  Oropharyngeal cancer as a driver of racial outcome disparities in squamous cell carcinoma of the head and neck: 10-year experience at the University of Maryland Greenebaum Cancer Center.

Authors:  Dan P Zandberg; Sandy Liu; Olga Goloubeva; Robert Ord; Scott E Strome; Mohan Suntharalingam; Rodney Taylor; Robert E Morales; Jeffrey S Wolf; Ann Zimrin; Joshua E Lubek; Lisa M Schumaker; Kevin J Cullen
Journal:  Head Neck       Date:  2015-06-30       Impact factor: 3.147

Review 7.  Head and neck cancer: changing epidemiology, diagnosis, and treatment.

Authors:  Shanthi Marur; Arlene A Forastiere
Journal:  Mayo Clin Proc       Date:  2008-04       Impact factor: 7.616

8.  The impact of health insurance status on the survival of patients with head and neck cancer.

Authors:  Joseph Kwok; Scott M Langevin; Athanassios Argiris; Jennifer R Grandis; William E Gooding; Emanuela Taioli
Journal:  Cancer       Date:  2010-01-15       Impact factor: 6.860

9.  Racial survival disparity in head and neck cancer results from low prevalence of human papillomavirus infection in black oropharyngeal cancer patients.

Authors:  Kathleen Settle; Marshall R Posner; Lisa M Schumaker; Ming Tan; Mohan Suntharalingam; Olga Goloubeva; Scott E Strome; Robert I Haddad; Shital S Patel; Earl V Cambell; Nicholas Sarlis; Jochen Lorch; Kevin J Cullen
Journal:  Cancer Prev Res (Phila)       Date:  2009-07-29

10.  Socioeconomic status, human papillomavirus, and overall survival in head and neck squamous cell carcinomas in Toronto, Canada.

Authors:  K P Chu; S Habbous; Q Kuang; K Boyd; M Mirshams; F-F Liu; O Espin-Garcia; W Xu; D Goldstein; J Waldron; B O'Sullivan; S H Huang; G Liu
Journal:  Cancer Epidemiol       Date:  2015-12-17       Impact factor: 2.984

View more
  2 in total

1.  Persistent ethnicity-associated disparity in anti-tumor effectiveness of immune checkpoint inhibitors despite equal access.

Authors:  Marcus A Florez; Jan O Kemnade; Nan Chen; Wendy Du; Anita L Sabichi; Daniel Y Wang; Quillan Huang; Courtney N Miller-Chism; Aparna Jotwani; Albert C Chen; David Hernandez; Vlad C Sandulache
Journal:  Cancer Res Commun       Date:  2022-07-26

Review 2.  The Key Differences between Human Papillomavirus-Positive and -Negative Head and Neck Cancers: Biological and Clinical Implications.

Authors:  Steven F Powell; Lexi Vu; William C Spanos; Dohun Pyeon
Journal:  Cancers (Basel)       Date:  2021-10-17       Impact factor: 6.575

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.